NCT06695507View on ClinicalTrials.gov

Upfront Ruxolitinib for Chronic Graft-vs-host Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 19, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Ruxolitinib

Participants will receive ruxolitinib for 6 months.

Trial Locations (1)

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER